Our in vitro findings with the anti-CTLA4/NKG2A aptamer align with the in vivo observations made by Huang et al. [20] and underscore the efficacy of our aptamer in facilitating CTLs targeted tumor lysis. The gene discussed is KLRC1; the disease is neoplasm.